Flare and Merck Partner to Advance FX-909 Combo in Cancer
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
